Sign Up Today and Learn More About SOMAÍ Pharmaceuticals Stock

Invest in or calculate the value of your shares in SOMAÍ Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

View More Companies

SOMAÍ Pharmaceuticals Stock (SOPH)

SOMAÍ Pharmaceuticals is a pharmaceutical and biotech company that specializes in cannabinoid-containing pharmaceutical medicines.

Invest Now Sell Shares

About SOMAÍ Pharmaceuticals Stock

Founded

2019

Industries

Software, Artificial Intelligence, Data and Analytics

At SOMAÍ, we are on a journey to build a leading global brand with the most robust portfolio of innovative cannabis-based therapeutics. We envision a world where people live healthy lifestyles empowered by natural cannabis medicine. Our company is dedicated to formulating innovative cannabis-based products to ensure a healthy and comfortable life. For that, we create a wide variety of medications for chronic patients and different conditions. We aim to design calm and satisfactory experience of administering, prescribing and purchasing cannabis-based medicine. SOMAÍ Pharmaceuticals is an EU-GMP European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal, and distributing EU GMP-certified cannabinoid-containing pharmaceuticals globally. SOMAÍ emphasizes scientific pharmacology applications with EU-GMP standards to effectively and consistently deliver treatments to the endocannabinoid system across all markets.

Stay in the know about the latest news on SOMAÍ Pharmaceuticals

The cannabis extraction debate: Are solvents or solventless methods better?

mjbizdaily • Apr 15, 2025

Ireland Could Make Great Cannabis Policy: Examining the Past to Look Forward

highlycapitalized • Apr 10, 2025

Product Dumping, White Labels, and Conflicts of Interest Lead to Global Cannabis Price Catastrophe

krautinvest • Apr 10, 2025

The Rise of Multi-Country Operators: Somai Targets 20 Countries by Year End

businessofcannabis • Mar 26, 2025

The Shift Toward Recognised Brands in Medical Cannabis

cannabishealthnews • Mar 26, 2025

Leadership team at SOMAÍ Pharmaceuticals

Chief Operating Officer and Co-Founder

George Bellow

Founder, Chairman and CEO

Michael Sassano

Join now and verify your accreditation status to gain access to:

SOMAÍ Pharmaceuticals Current Valuation
SOMAÍ Pharmaceuticals Stock Price
SOMAÍ Pharmaceuticals Management
Available deals in SOMAÍ Pharmaceuticals and all other companies with relevant Deal Offering documents
EquityZen's proprietary data and insights, which may include

SOMAÍ Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
SOMAÍ Pharmaceuticals Revenue and Financials
SOMAÍ Pharmaceuticals Highlights
SOMAÍ Pharmaceuticals Business Model
SOMAÍ Pharmaceuticals Risk Factors

SOMAÍ Pharmaceuticals Research Report from SACRA Research

Join Now

Trading SOMAÍ Pharmaceuticals Stock

How to invest in SOMAÍ Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like SOMAÍ Pharmaceuticals through EquityZen funds. These investments are made available by existing SOMAÍ Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell SOMAÍ Pharmaceuticals stock?

Shareholders can sell their SOMAÍ Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."

More Like SOMAÍ Pharmaceuticals

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the U.S. Securities and Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen.

EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They do not refer to any publicly traded stock. EquityZen does not have an affiliation with, formal relationship with, or endorsement from any of the companies featured and none of the statements on the site should be attributed to those companies.

“Market Activity” and other transactional data displayed on this website is compiled by EquityZen and is confidential and historical in nature. Unauthorized use, distribution or reproduction is prohibited. Transactional information does not guarantee future investment results. EquityZen cannot guarantee finding or approving a transaction at any displayed price.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2025 EquityZen Inc. All rights reserved.